Pfizer posts Q1FY22 PAT of Rs. 199.91 Cr

The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.

Pfizer and BioNTech expects third dose clinical studies of COVID-19 vaccine in August

The companies anticipate clinical studies to begin in August, subject to regulatory approvals

Margins impacted by high expenses for Pfizer: ICICI Securities

Adjusted PAT declined 18.8% YoY

Pfizer registers Q4FY21net profit at Rs 100 Cr

Revenue from operations for the year ended March 31, 2021 is ?2,239 crore

Pfizer registers Q3FY21 PAT at Rs. 141.24 Cr

The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.

Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future

India in the Changing Landscape of Life-Sciences Research & Development

Valneva and Serum Institute end chikungunya vaccine partnership

Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries

Merck’s KEYTRUDA–Padcev combo delivers survival gains in Phase 3 bladder cancer trial

Valneva Phase 2 data for Lyme disease vaccine candidate shows striking immune response

Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020

FDA nod to groundbreaking bladder cancer combo therapy for surgery patients

Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options